237 related articles for article (PubMed ID: 31663382)
1. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?
Rehman S; Nabi B; Zafar A; Baboota S; Ali J
Expert Opin Drug Deliv; 2019 Dec; 16(12):1355-1366. PubMed ID: 31663382
[No Abstract] [Full Text] [Related]
2. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
3. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R
Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538
[TBL] [Abstract][Full Text] [Related]
4. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
5. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
[TBL] [Abstract][Full Text] [Related]
6. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.
Sharma S; Lohan S; Murthy RS
Drug Dev Ind Pharm; 2014 Jul; 40(7):869-78. PubMed ID: 23600649
[TBL] [Abstract][Full Text] [Related]
7. The application of mucoadhesive polymers in nasal drug delivery.
Jiang L; Gao L; Wang X; Tang L; Ma J
Drug Dev Ind Pharm; 2010 Mar; 36(3):323-36. PubMed ID: 19735210
[TBL] [Abstract][Full Text] [Related]
8. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson's disease.
Rao M; Agrawal DK; Shirsath C
Drug Dev Ind Pharm; 2017 Jan; 43(1):142-150. PubMed ID: 27533244
[TBL] [Abstract][Full Text] [Related]
9. N,N,N‑trimethyl chitosan modified flaxseed oil based mucoadhesive neuronanoemulsions for direct nose to brain drug delivery.
Pardeshi CV; Belgamwar VS
Int J Biol Macromol; 2018 Dec; 120(Pt B):2560-2571. PubMed ID: 30201564
[TBL] [Abstract][Full Text] [Related]
10. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease.
Saha P; Kathuria H; Pandey MM
J Control Release; 2023 Jun; 358():293-318. PubMed ID: 37061193
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Administration of chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease.
Gartziandia O; Herrán E; Ruiz-Ortega JA; Miguelez C; Igartua M; Lafuente JV; Pedraz JL; Ugedo L; Hernández RM
J Biomed Nanotechnol; 2016 Dec; 12(12):2220-30. PubMed ID: 29372975
[TBL] [Abstract][Full Text] [Related]
12. A neoteric annotation on the advances in combination therapy for Parkinson's disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus.
Unnithan D; Sartaj A; Iqubal MK; Ali J; Baboota S
Expert Opin Drug Deliv; 2024 Mar; 21(3):437-456. PubMed ID: 38507231
[TBL] [Abstract][Full Text] [Related]
13. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam.
Abdel-Bar HM; Abdel-Reheem AY; Awad GA; Mortada ND
J Pharm Pharm Sci; 2013; 16(3):456-69. PubMed ID: 24021293
[TBL] [Abstract][Full Text] [Related]
15. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.
Aly AE; Waszczak BL
Expert Opin Drug Deliv; 2015; 12(12):1923-41. PubMed ID: 26289676
[TBL] [Abstract][Full Text] [Related]
16. inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
Rinaldi F; Seguella L; Gigli S; Hanieh PN; Del Favero E; Cantù L; Pesce M; Sarnelli G; Marianecci C; Esposito G; Carafa M
J Control Release; 2019 Jan; 294():17-26. PubMed ID: 30529726
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug.
Alam MI; Baboota S; Ahuja A; Ali M; Ali J; Sahni JK; Bhatnagar A
Int J Pharm; 2014 Aug; 470(1-2):99-106. PubMed ID: 24810241
[TBL] [Abstract][Full Text] [Related]
18. Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review.
Kapoor A; Hafeez A; Kushwaha P
Curr Drug Deliv; 2024; 21(5):709-725. PubMed ID: 37365787
[TBL] [Abstract][Full Text] [Related]
19. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery.
Shringarpure M; Gharat S; Momin M; Omri A
Expert Opin Drug Deliv; 2021 Feb; 18(2):169-185. PubMed ID: 32921169
[TBL] [Abstract][Full Text] [Related]
20. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.
Sabir F; Ismail R; Csoka I
Drug Discov Today; 2020 Jan; 25(1):185-194. PubMed ID: 31629966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
